Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic Substances
Sub-IndustryN/A
SectorMedical
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Palatin Technologies (NASDAQ:PTN) Frequently Asked Questions
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the NASDAQ under the ticker symbol "PTN."
When is Palatin Technologies' next earnings date?
What is the consensus analysts' recommendation for Palatin Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.
Has Palatin Technologies been receiving favorable news coverage?
Headlines about PTN stock have trended neutral this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Palatin Technologies earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI) and BG Medicine (BGMD).
Who are Palatin Technologies' key executives?
Palatin Technologies' management team includes the folowing people:
- Dr. John K. A. Prendergast Ph.D., Co-Founder & Non-Exec. Chairman (Age 64)
- Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 56)
- Mr. Stephen T. Wills CPA, MST, CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec. (Age 61)
- Burns McClellan, VP of Investor Relations
- Dr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer
How do I buy shares of Palatin Technologies?
Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Palatin Technologies' stock price today?
One share of PTN stock can currently be purchased for approximately $0.8019.
How big of a company is Palatin Technologies?
Palatin Technologies has a market capitalization of $162.84 million.
What is Palatin Technologies' official website?
MarketBeat Community Rating for Palatin Technologies (NASDAQ PTN)
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
